Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus ETHINYL ESTRADIOL ETONOGESTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus ETHINYL ESTRADIOL ETONOGESTREL.
AYGESTIN vs ETHINYL ESTRADIOL; ETONOGESTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
ETHINYL ESTRADIOL is an estrogen; ETONOGESTREL is a progestin. The combination suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial receptivity.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
One vaginal ring (0.120 mg etonogestrel/0.015 mg ethinyl estradiol per day) inserted vaginally and left in place for 3 weeks, followed by a 1-week ring-free period.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Ethinyl estradiol: ~13 hours (range 7-20 h); etonogestrel: ~25 hours (range 15-36 h). At steady state, elimination half-life extends to 20-30 h for etonogestrel.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Urine (60-70% as metabolites, <10% unchanged), feces (20-30% via biliary elimination).
Category C
Category D/X
Progestin
Progestin